IkT-148009

IkT-148009 · ABLi Therapeutics, Inc.

Drug timelines are a Plus or Pro feature.

4 regulatory and trial events tracked for IkT-148009, covering 2024-10-16 to 2025-11-19. Get the full timeline:

Most recent: Clinical Trial Update: A Randomized, Double-Blind, Placebo-Controlled Trial of IkT-148009 in Untreated Parkinson's Disease [Phase 2]